tapebrief

CRL · Q2 2025 Earnings

Cautious

Charles River Laboratories

Reported August 6, 2025

30-second summary

30-second take: Revenue of $1.03B was essentially flat YoY (+0.6% reported, -0.5% organic) with non-GAAP EPS of $3.12, and management raised the DSA segment outlook by ~150bps while reaffirming a still-negative consolidated organic growth range of -3.0% to -1.0% for FY2025. The two real signals: DSA bookings have climbed from 0.80x to 0.93x over 18 months (though Q2 alone dipped to 0.82x), and the multi-year NHP Cambodia investigation was conclusively cleared by Interior, Fish & Wildlife, and DOJ — removing a tail risk shareholders had been pricing. The strategic review is "well underway" with no interim updates planned, which keeps optionality elevated but visibility low.

Headline numbers

EPS

Q2 FY2025

$3.12

Revenue

Q2 FY2025

$1.03B

+0.6% YoY

Operating margin

Q2 FY2025

9.7%

Key financials

Q2 FY2025
MetricQ2 FY2025YoY
Revenue$1.03B+0.6%
EPS$3.12—
Operating margin9.7%—

Guidance

Prior quarter data unavailable — comparison not possible.

Segment KPIs

Q2 FY2025
SegmentQ2 FY2025YoY
Research Models and Services (RMS)$0.213B+3.3%
Discovery and Safety Assessment (DSA)$0.618B-1.5%
Manufacturing Solutions$0.201B+4.4%

Other KPIs

Q2 FY2025
SegmentQ2 FY2025
Non-GAAP Operating Margin22.1%
RMS Non-GAAP Operating Margin25.3%
DSA Non-GAAP Operating Margin27.4%
Manufacturing Non-GAAP Operating Margin32.8%
RMS Organic Revenue Growth2.3%
DSA Organic Revenue Growth-2.4%
Manufacturing Organic Revenue Growth2.9%
Total Organic Revenue Growth-0.5%

Management tone

Management's posture this quarter shifted from defensive uncertainty to disciplined cautious-positive — but stopped well short of declaring recovery. The most concrete change is on DSA: "the DSA business is stabilized and is beginning to show signs of gradual progress." Compared to prior framings of "watching for stabilization," this is an affirmative statement, backed by the 18-month book-to-bill trajectory and a 150bps guidance improvement for the segment. The signal: management now has enough conviction to modestly add DSA headcount, which is the first hiring posture change in this cycle.

On the NHP Cambodia overhang, the tone moved from contingent to resolved: "The Department of Interior and U.S. Fish and Wildlife Service cleared for legal entry into the United States all of the NHP shipments from Cambodia from late 2022 and early 2023 that were under investigation. In addition, we have been informed that the U.S. Department of Justice is no longer conducting investigations." This is a binary risk removal — three years of regulatory and litigation exposure terminated in a single paragraph. Management did not editorialize, which is itself notable; the absence of self-congratulation signals confidence in the underlying business case.

Despite the wins, management deliberately suppressed forward enthusiasm: "We have not factored in further demand improvements this year" and "we continue to take a measured and prudent approach to our outlook." Pairing improved DSA guidance with explicit refusal to extrapolate suggests management is preserving sandbag room — particularly relevant given the strategic review underway. The framing "this thorough process takes time, but we are moving forward with a sense of urgency and do not intend to provide updates until the strategic review has been completed" suggests active engagement with alternatives while consciously dampening short-term expectations to avoid disappointment if the process extends.

On policy risk, management was direct that the bigger impact is deferred: tariffs, MSN pricing, and NIH funding cuts have had "minuscule" effect on 2025 but management explicitly expects "greater impact in 2026 than 2025." This is a quiet flag that 2026 setup is not as clean as the improving 2025 trajectory might suggest.

Recurring themes management leaned on this quarter:

Demand stabilization and gradual improvement trajectoryDSA segment outperformance and bookings recoveryCost structure optimization delivering $175M+ run rate savingsCapital allocation focus: $350M share repurchase and debt reductionNHP supply chain resolution removing regulatory overhangNAMS portfolio expansion as long-term strategic priority

Risks management surfaced:

Biotech funding environment remains constrained for smaller biotechsCommercial CDMO revenue loss creating ~$20M first-half headwind in second halfDSA net book-to-bill below 1.0x indicating uneven demand recoveryElevated tax rate in Q3 (25-30%) from OB3 legislation headwindNIH budget uncertainty and $3M NIH National Institute on Aging contract scope reduction

Q&A highlights

Elizabeth Anderson · Evercore ISI

Asked about current demand environment across pharma and biotech segments, and what has been observed in July and early August

Management indicated demand is stabilizing for pharma with revenue and proposals up sequentially. Pharma feels stable and improving. Biotech presents a mixed picture with smaller companies cash-constrained until capital markets open, while mid-tier biotech is performing better. DSA net book-to-bill has shown steady upward trajectory for 18 months.

Pharma revenue up sequentiallyProposals up year-over-year and sequentiallyDSA net book-to-bill steady upward trajectory for last 18 monthsBook-to-bill range 0.8-0.93 for first half of year

Eric Coldwell · Baird

Asked to dissect 2Q CDMO performance including the $20 million client wind-down and margin impact, and requested details on U.S. Fish and Wildlife clearing Cambodian NHPs

Management explained the $20 million is a wind-down across first half with higher-than-normal margins and a one-time payment in Q2. The Cambodian NHP clearance provides regulatory flexibility to use animals already in country and import new ones, enabling better planning for NHP toxicology work.

$20 million wind-down revenue across first half (not just Q2)Margins on this work slightly higher than normalOne-time payment received in Q2 onlyCambodian NHP clearance removes regulatory constraints

Dave Windley · Jefferies

Asked for clarification on CDMO client headwind calculation and full-year impact, and questioned how DSA can achieve revenue growth with book-to-bill below one given backlog dynamics

Confirmed approximately $39 million headwind from CDMO client changes ($20 million in first half, $0 in second half), representing roughly 500 basis points to manufacturing solutions segment. Explained DSA backlog of 10 months can offset below-one book-to-bill through conversion and mix dynamics, with cancellations offset by new work types like general toxicology.

CDMO headwind approximately $39 million for year (slightly below 500 basis points)Original guidance discussed $40 million headwind from two commercial clientsDSA backlog approximately 10 monthsBacklog conversion rates have varied widely historically

Patrick Donnelly · Citi

Asked about confidence in hiring decisions given cycles, whether 0.9 book-to-bill supports DSA growth next year, pricing stability, and margin implications

Management stated hiring is catching up to current activity levels, not getting ahead, and is people-driven to maintain quality and speed. Avoided specific guidance on next year but indicated pharma and large biotech trajectories are positive. Pricing is stable with mix favorability helping price-mix equation. Merit increase of 3.5% in July impacts salary costs.

Hiring is catching up to current demand, not ahead of curve3.5% merit increase effective July 1stPricing in DSA stable with spot pricing solidMix favorability helping price-mix equation in first half

Casey Woodring · JP Morgan

Asked about drivers of higher cancellations in longer-term post-IND work, margin differentials, and outlook on MSN pricing and tariff impacts from recent administration actions

Management explained cancellations are client portfolio prioritization, shifting emphasis to clinical work. Margin differentials between earlier and later stage work are not significant. Regarding policy headwinds (MSN pricing, tariffs, NIH funding), management has seen minuscule adverse impact so far and expects greater impact in 2026 than 2025. Guidance accommodates for potential rougher conditions.

Cancellations driven by client prioritization toward clinical workMargin profile comparable between different types of workMinuscule adverse impact from MSN pricing, tariffs, and NIH funding cuts so farExpects greater impact from policy headwinds in 2026 than 2025

What to watch into next quarter

DSA net book-to-bill in Q3: Q2 dipped to 0.82x from H1 average of 0.93x. Watch whether Q3 reverses back above 0.90x to validate the "gradual progress" narrative, or whether 0.82x marks a plateau that undermines the improved FY guide.

DSA H2 margin compression from hiring and the 3.5% July merit increase: the segment delivered 27.4% non-GAAP op margin in Q2. Watch whether H2 holds above 25% or whether modest staffing additions hit harder than management implied.

Strategic review outcome: management said no interim updates. A resolution (divestiture, take-private, restructuring) would be the dominant share-price catalyst; watch the Q3 release for any change in language about "moving forward with a sense of urgency."

2026 policy headwind quantification: management flagged MSN pricing, tariffs, and NIH funding as bigger 2026 issues. Watch the Q3 call for the first specific dollar-impact framing on any of the three.

Manufacturing organic growth ex-CDMO wind-down: the $39M client headwind is fully absorbed in H1, meaning H2 should show cleaner organic trends. Watch whether segment organic prints above 5% in Q3, which would suggest underlying Manufacturing demand is healthier than the FY "essentially flat" guide implies.

Sources

  1. Charles River Laboratories Q2 2025 earnings press release, filed 2025-08-06. https://www.sec.gov/Archives/edgar/data/1100682/000110068225000032/crl2q25earningsrelease.htm
  2. Charles River Laboratories Q2 2025 earnings conference call transcript (prepared remarks and Q&A).

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.